Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP ® (capivasertib) in combination with abiraterone and androgen deprivation therapy ...

TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in ...

Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context. The widespread adoption of PSMA PET imaging has ...

An FDA advisory panel has voted 7-1, with one abstention, to recommend expanding the use of AstraZeneca’s capivasertib (Truqap) for PTEN-deficient metastatic hormone-sensitive prostate cancer. The ...

Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...

An FDA advisory panel has recommended expanding AstraZeneca’s capivasertib (Truqap) for use with abiraterone and prednisone in PTEN-deficient metastatic hormone-sensitive prostate cancer, citing ...

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.

Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...